DBPR112
DBPR112 is an orally bioavailable furanopyrimidine inhibitor targeting the EGFR ATP-binding site, demonstrating potent activity against wild-type (IC50=15 nM) and L858R/T790M mutant (IC50=48 nM) forms. It has shown significant antitumor efficacy in preclinical research models, supporting its investigation in oncology studies for EGFR-driven cancers.
Product Specifications
CAS Number
1226549-49-0
Product Name Alternative
DBPR112, DBPR-112, DBPR 112, EGFR (wt), EGFR (L858R/T790M), EGFRL858R/T790M, EGFRWT
Field of Research
Cardiovascular Research, Signal Transduction
Purity
98.29% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (9.37 mM) ; DMSO:225 mg/mL (421.65 mM)
Smiles
CN (C) C\C=C\C (=O) Nc1cccc (c1) -c1c (oc2ncnc (N[C@H] (CO) c3ccccc3) c12) -c1ccccc1
Molecular Formula
C32H31N5O3
Molecular Weight
533.62
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Explore Other Products
Browse additional items from our catalog
Recombinant Macaca mulatta CD40 ligand (CD40LG), partial
Recombinant Macaca mulatta CD40 ligand (CD40LG), partial
Recombinant Macaca mulatta CD40 ligand (CD40LG), partial